

PERSONAL DATA

Clelia Pellicano

work address

Laboratory of Neuropsychiatry Department of Clinical and Behavioral Neurology,
IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy Phone (+39) 06 51502193
c.pellicano@hsantalucia.it

EDUCATION,
QUALIFICATIONS AND
FELLOWSHIPS

Novembre 2020	Good Clinical Practice, GCP certificate
January 2015-December 2016	Acupuncture and Traditional Chinese Medicine degree, Scuola di Agopuntura Energetica e Tradizionale SAET, Rome, Italy
November 2014- November 2017	PhD with full mark and honors, Clinical/Experimental Neuroscience and Psychiatry, Sapienza University, Rome, Italy
May 2013-2014	Certificate of full registration as a medical practitioner with license to practice, General Medical Council (GMC), UK
May 2013-October 2013	Visiting Researcher, Department of Medicine, section of Neurodegeneration and Neuroinflammation, Imperial College, London, UK
July 200-July 2014	Neurology Residency, with full marks 70/70 and honors, Sapienza University, Rome, Italy; Neurologist
July 2007-November 2008	Postdoctoral Fellow at the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
March 2007	Professional practice examination (Italy), (M55717)
November 2006	License to practice medicine, Italy
September 2000-July 2006	MD degree with full marks 110/110 and honors, School of Medicine and Surgery, Sapienza University. Thesis title: 'Dopamine Transporter in Peripheral Blood Mononuclear Cells in Parkinson's disease and Essential Tremor: Correlation with DAT-scan analysis'
September 1995-July 2000	High School Diploma with full marks 100/100, Liceo Giulio Cesare, Rome, Italy

WORKING EXPERIENCE

March 2020 - to present	Laboratory of Neuropsychiatry Department of Clinical and Behavioral Neurology Saint Lucia Foundation IRCCS; Rome, Italy
August 2018 - February 2020	Neurologist, Neurology Unit, Belcolle Hospital, NHS, Str Sarmartinese, 01100, Viterbo, Italy
April 201 - July 2018	Consultant Neurologist, CGH, Compagnie Generale des Hopitaux srl, Via Nomentana 173, 00161 Rome, Italy
June 2015 - July 2018	Consultant Neurologist, BIOS Spa, Via del Fornaccio 1-3, 00062 Bracciano (Rome), Italy
March 2015 - July 2018	Consultant Neurologist, Studio Medico San Giorgio, Centre of Neurorehabilitation, Via Fontana dell'Oste 78A, 00034 Colferro (Rome), Italy
March 2015 - July 2018	Consultant Neurologist, Italian Union Against Muscular Dystrophy (UILDm), Via Prospero Santacroce, S, 00167 Rome, Italy
September 2014 - December 2016	Clinical Assistant at Movement Disorders Unit, Sant'Andrea Hospital, NHS, Rome, Italy
January 2014 - to present	Staff Scientist, Laboratory of Neuropsychiatry Department of Clinical and Behavioral Neurology Saint Lucia Foundation IRCCS; Rome, Italy
January 2014 -December 2015	Clinical Attendance at Centre for treatment and management of Spasticity (Botulin Toxin), Sant'Andrea Hospital, NTIS, Rome, Italy
January 2004 - July 2014	Clinical Attendance at Movement Disorders Unit, Sant'Andrea Hospital, NHS, Rome, Italy

SCIENTIFIC COLLABORATIONS AND CLINICAL TRIALS

January 2021-to present	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Tavapadon As Adjunctive Therapy For Parkinson's Disease In Levodopa-Treated Adults With Motor Fluctuations CINempeo-3 Trial); deputy PI
October 2020-to present	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Two Fixed Doses Of Tavapadon In Early Parkinson's Disease (Tempo-1 Trial); deputy PI
October 2020-to present	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless); deputy PI
July 2020-to present	Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12*Month Open-Label Treatment; deputy PI
March 2020-to present	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of Gantenerumab In Patients With Early (Prodromal To Mild) Alzheimer's Disease; clinical investigator

December 2017-to present	Winner of the project (Co-PI) presented on the finalized research call framework of the year 2016 funded on the year 2014-2015), code GR-2016-02361783, entitled "Unraveling neuroimaging biomarkers of vascular parkinsonism using multimodal, conventional and unconventional MRI techniques to investigate their role in determining the peculiar clinical phenotype of the disease role: Principal Investigator, founded for € 384300, conducted at the IRCCS Fondazione Santa Lucia in Rome.
January 2016-February 2019	European Project Horizon 2020 "PICASO"- A Personalized Integrated Care Approach for Service Organizations and Care Models for Patients with Multi-Morbidity and Chronic Conditions; clinical investigator
January 2015-March 2018	European Project Horizon 2020 "PD MANAGER" - mHealth platform for Parkinson's disease management; clinical investigator
June 2014-July 2015	Multicentric observational study "PREDICT" on PREDICTors of quality of life and caregiver burden in Parkinson's disease; clinical investigator
January 2011-June 2012	Multicentric observational study "REASON" on therapy management in Parkinson's Disease patients; clinical investigator
January 2006-December 2008	Multicentric observational study "PRIAMO" on non-motor symptoms of extrapyramidal syndromes; clinical investigator

SCIENTIFIC PUBLICATION

2021	Strafella C, Caputo V, Termine A, Assogna F, Pellicano C , Pontieri FE, Macchiusi L, Minozzi G, Gambardella S, Centonze D, Bossù P, Spalletta G, Caltagirone C, Giardina E and Cascella R. <i>Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions</i> . (2021) Front. Genet, 12:651971. doi: 10.3389/fgene.2021.651971
2021	Assogna F, Liguori C, Cravello L, Macchiusi L, Belli C, Placidi F, Pierantozzi M, Stefani A, Mercuri B, Izzi F, Caltagirone C, Mercuri NB, Pontieri FE, Spalletta G, Pellicano C . <i>Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease</i> . J Pers Med. 2021 Jan 16;11 (1):51. doi: 10.3390/jpm11010051. PMID: 33467021; PMCID: PMC7830588.
2020	Marcante A, Di Marco R, Gentile G, Pellicano C , Assogna F, Pontieri FE, Spalletta G, Macchiusi L, Gatsios D, Giannakis A, Chondrogiorgi M, Konitsiotis S, Fotiadis DI, Antonini A. <i>Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease</i> , Sensors (Basel). 2020 Dec 28;21(1):128. doi: 10.3390/s21010128, PMID: 33379174; PMCID: PMC7794778.
2020	Piras F, Vecchio D, Assogna F, Pellicano C , Ciullo V, Banaj N, Edden RAE, Pontieri FE, Piras F, Spalletta G. <i>Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators</i> . J Pers Med. 2020 Dec 28;11(1):16. doi: 10.3390/jpm11010016. PMID: 33379134; PMCID: PMC7823866.
2020	Almeida SS, Zizzi FB, Cattaneo A, Comandini A, Di Dato G, Lubrano E, Pellicano C , Spallone V, Tongiani S, Torta R. <i>Management and Treatment of Patients With Major Depressive Disorder and Chronic Diseases: A Multidisciplinary Approach</i> . Front Psychol. 2020 Sep 24; 11:542444. doi: 10.3389/fpsyg.2020.542444. PMID: 33101117; PMCID: PMC7546762.
2020	Gatsios D, Antonini A, Gentile G, Marcante A, Pellicano C , Macchiusi L, Assogna F, Spalletta G, Gage H, Touray M, Timotijevic L, Hodgkins C, Chondrogiorgi M, Rigas G, Fotiadis DI, Konitsiotis S. <i>Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trials</i> . JMIR Mhealth Uhealth. 2020 Jun 29;8(6): e 16414. doi: 10.2196/16414. PMID: 32442154; PMCID: PMC7367523.

- 2020 Timotijevic L, Hodgkins CE, Banks A, Rusconi P, Egan B, Peacock M, Seiss E, Touray MML, Gage H, **Pellicano C**, Spalletta G, Assogna F, Giglio M, Marcante A, Gentile G, Cikajlo I, Gatsios ADS, Konitsiotis S, Fotiadis D. *Designing a mHealth clinical decision support system for Parkinson's disease: a theoretically grounded user needs approach*. BMC Med Inform Decis Mak. 2020 Feb 19;20(1):34. doi: 10.1186/s12911-020-1027-1. PMID: 32075633; PMCID: PMC7031960.
- 2019 Wilson H, Niccolini F, **Pellicano C**, Politis M. *Cortical thinning across Parkinson's disease stages and clinical correlates*. J Neurol Sci. 2019 Mar 15; 398:31-38
- 2019 Assogna F, **Pellicano C**, Cravello L, Savini Cs, Macchiusi L, Pierantozzi M, Stefani A, Mercuri B, Caltagirone C, Pontieri FE, Spalletta G. *Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism*. Brain Behav. 2019 2019 Dec;9(12): e01448
- 2019 Assogna F, **Pellicano C**, Savini C, Macchiusi LS, Pellicano GR, Alborghetti M, Caltagirone C, Spalletta G, Pontieri FE. *Drug Choices and Advancements for Managing Depression in Parkinson's Disease*. Curr Neuropharmacol. 2019 Oct 15.[Epub ahead of print]
- 2018 Campo F, Carletti R, Rusconi M, **Pellicano C**, Pontieri FE, Di Gioia CR, de Vincentiis M. *Alpha-synuclein in Saliv. gland as biomarker for Pækinson's disease*. Rev Neurosci 2018 Nov 24. Pii: /j/revneuro.ahead-of-print/revneuro-2018-0064/revneuro-2018-0064.xml. doi: 10.1515/revneuro-2018-0064. [Epub ahead of print]
- 2018 Assogna F, **Pellicano C**, Cravello L, Savini C, Pierantozzi M, Mercuri B, Caltagirone C, Pontieri FE, Spalletta G, Stefani A. *Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients*. Brain Behav. 2018 Oct;8(10): e01094
- 2018 Antonini A, Gentile G, Giglio M, Marcante A, Gage H, Touray MML, Fotiadis DI, Gatsios D, Konitsiotis S, Timotijevic L, Hodgkins C, Biundo R, **Pellicano C**, PD_Manger consortium. *Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial*. Trials. 2018 sep 14.
- 2018 Orfei MD, Assogna F, **Pellicano C**, Pontieri FE, Caltagirone C, Pierantozzi M, Stefanini A, Spalletta G. *Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates*. Parkinsonism Relat Disord. 2018 Sept; 54:62-67
- 2017 **Pellicano C**, Assogna F, Cellupica N, Piras F, Pierantozzi M, Stefanini A, Mercuri B, Caltagirone C, Pontieri FE and Spalletta G. *Neuropsychiatric and Neuropsychological profile of early Progressive Supranuclear Palsy and Parkinson's Disease*. Parkinsonism Relat Disord. 2017 Dec; 45:50-56
- 2017 Latino P, Tagliente S, **Pellicano C**, Giovannelli M. and Pontieri FE. *Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson's Disease: An Update on the Effects of Cognitive Functions*. Advances in Parkinson's Disease, 2017; 6: 13-23
- 2017 Carletti R, Campo F, Fusconi M, **Pellicano C**, De Vincentiis M, Pontieri FE, Di Gioia CR. *Phosphorylated α -synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease*. Parkinsonism Relat Disord. 2017 May; 38:99-101
- 2015 **Pellicano C**, Assogna F, Cravello L, Langella R, Caltagirone C, Spalletta G, Pontieri FE. *On the relationship between side of onset and cognition in Parkinson disease: Response from the authors*. Parkinsonism Relat Disord. 2015 Dec; 21(12): 1481-2
- 2015 **Pellicano C**, Niccolini F, Wu K, O'Sullivan SS, Lawrence AD, Lees AJ, Piccini P, Politis M. *Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders*. J Neurol 2015 Dec; 262(12): 2653-61 Epub 2015 Sep 26.

- 2015 **Pellicano C**, Assogna F, Cravello L, Langella R, Caltagirone C, Spalletta G, Pontieri FE. *Neuropsychiatric and cognitive symptoms and boby side onset of parkinsonism in unmedicated Parckinson's disease patients*. Parkinsonism Relat Disord. 2015 Sep; 21:1096-100
- 2015 Cacciari C, **Pellicano C**, Cravello L, Assogna F, Piras F, Paravia P, Gili T, Iorio M, Stefanini A, Pierantozzi M, Caltagirone C, Pontieri FE, Spalletta G. *Unraveling predictors affecting compliance to MRI in Parkinson's disease*. Parkinsonism Relat Disorde 2015 Aug; 21:964-7
- 2015 Pontieri FE, Assogna F, **Pellicano C**, Cacciari C, Pannunzi S, Marrone A, Danese E, Caitagirone C, Spalletta G. *Sociodemographic, neuropsychiatric and cognitive chracteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease*. Eur Neuropsychopharmacol. 2015 Jan; 25:69-76
- 2014 Latino P, **Pellicano C**, Pontieri FE, Giovannelli M. *Treatment with botulism toxin for anti-MAG negropgthy-related arm tremor*. Neurol Sci. 2015 Feb; 36:333-4. Epub 2014 Aug 5
- 2014 Guidoni SV, **Pellicano C**, La Starza S, Spalloni A, Rasura M. *Tako tsubo and ischemic stroke in a patient with Alzheimer's disease*. Aging Clin Exp Res. 2014 Dec; 26:673-5. Epub 2014 Apr 24
- 2013 **Pellicano C**, Benincasa D, Fanciulli A, Latino P, Giovannelli M, Pontieri FE. *The impact of extended release dopamine agonists on prescribing patterns for thercopy of early Parchinson's disease: an observational study*. Eur J Med. Res. 2013 Dec 21; 18:60
- 2013 Tinazzi M, Abbruzzese G, Antonini A, Ceravolo R, Fabbrini G, Lessi P, Barone P; **REASON Sandy Group**. *Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study*. Parkinsonism Relat Disord. 2013 Dec; 19:1130-5
- 2013 Fabbrini G, Abbruzzese G, Barone P, Antonini A, Tinazzi M, Castegnaro G, Rizzoli S, Morisky DE, Lessi P, Ceravolo R; **REASON study group**. *Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's desease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items"*. Neurol Sci. 2013 Nov; 34: 2015-22
- 2013 **Pellicano C**, Kane RL, Gallo A, Xiaobai L, Stern SK, Ikonomidou VN, Evangelou IE, Ohayon JM, Ehrmantraut M, Cantor FK, Bagnato F. *Cognitive Impairment and Its Relation to Imaging Measures in Multiple Sclerosis: A Study Using a Computerized Battery*. J Neuroimaging 2013 Jul; 23: 445-52
- 2012 Campbell Z, Sahm D, Donohue K, Jamison J, Davis M, **Pellicano C**, Auh S, Ohayon J, Frank JA, Richert N, Bagnato F. *Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis*. Neurology. 78:1493-9, 2012
- 2012 Morgante L, Colosimo C, Antonini A, Marconi R, Meco G, Pederzoli M, Pontieri FE, Cicarelli G, Abbruzzese G, Zappulla S, Ramat S, Manfredi M, Bottacchi E, Abrignani M, Berardelli A, Cozzolino A, Paradiso C, De Gaspari D, Morgante F, Barone P; **PRIAMO Study Group**. *Psychosis associated to Pckingon's disease in the early stages: relevance of cognitive decline and depression*. J Neurol Neurosurg Psychiatry. 83:76-82, 2012
- 2012 **Pellicano C**, Assogna F, Piras F, Caltagirone C, Pontieri FE, Spalletta G. *Regional cortical thickness and cognitive functions in non-demented Parkinson's disease patients: a pilot study*. Eur J Neurol, 19; 172-5, 2012
- 2011 Buttarelli FR, Fanciulli A, **Pellicano C**, Pontieri FE. *The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders*. Curr Neuropharmacol. 9:278-88, 2011
- 2011 Benincasa D, **Pellicano C**, Fanciulli A, Ponderi FE. *Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinsmr's disease*; Mov Disord. 26:355-7, 2011
- 2010 Bagnato F, Salman Z, Kane R, Auh Cantor FK, Ehrmantraut M, Gallo A, Ikonomidou VN, Ohayon J, **Pellicano C**, Stern SK, McFarland HF. *T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis*. Mult Scler. 16:1203-12, 2010

- 2010 Assogna F, Pontieri FE, Cravello L, Peppe A, Pierantozzi M, Stefani A, Stanzione P, **Pellicano C**, Caltagirone C, Spalletta G. *Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease*. J Int Neuropsychol Soc.; 16:867-76, 2010
- 2010 Bomboi G, Ikonomidou VN, Pellegini S, Stern SK, Gallo A, Aub S, Evangelou IE, Agarwal J, **Pellicano C**, Ohayon JM, Cantor FK, Ehrmantraut M, McFarland HF, Kane RL, Bagnato F. *Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis*. J Neuroimaging, 21: e57-63, 2010
- 2010 **Pellicano C**, Gallo A, Li X, Ikonomidou VN, Evangelou IE, Ohayon JM, Stern SK, Ehrmantraut M, Cantor F, McFarland HF, Bagnato F. *Relationship of cortical atrophy of fatigue in patients with multiple sclerosis*. Arch Neurol, 67:447-53, 2010
- 2009 Buttarelli PR, Circella A, **Pellicano C**, Tiple D, Giovannelli M, Colosimo C, Pontieri FE. *Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy*. J Neural Transm, 116:161-5, 2009
- 2009 Buttarelli FR, Capriotti G, **Pellicano C**, Prosperi D, Circella A, Festa A, Giovannelli M, Tofani A, Pontieri FE, Scopinaro F. *Central and peripheral dopamine transporter reduction in Parkinson's disease*. Neurol Res, 31:687-91, 2009
- 2009 **Pellicano C**, Benincasa D, Giovannelli M, Buttarelli FR, Ruggeri S & Pontieri FE. *Entacapone in elderly parkinsonian patients experiencing levodopa-related wearing-off: a pilot study*. Neurol Res. 31 (1): 74-6, 2009
- 2008 Gaindh D, Jeffries N, Ohayon J, Richert ND, **Pellicano C**, Frank JA, McFarland H, Bagnato F. *The effect of interferon beta-1b on size of short-lived enhancing lesions with multiple sclerosis*. Expert Opin Biol Ther, 8:1823-9, 2008
- 2008 Benincasa D, Romano A, Mastronardi L, **Pellicano C**, Bozzao A & Pontieri FE. *Hemiparkinsonism due to frontal meningioma*. Acta Neurol Belg Mar 108(1): 29-32, 2008
- 2008 Buttarelli FR, **Pellicano C**, Pontieri FE. *Neuropharmacology and behaviour in planarians: translations to mammals*. Comp Biochem Physiol C, 147:399-408, 2008
- 2007 **Pellicano C**, Buttarelli FR, Circella A, Tiple D, Giovannelli M, Benincasa D, Colosimo C & Pontieri FE. *Dopamine transporter immunoreactivity in peripheral blood lymphocytes Parkinson's disease from essential tremor*. J Neural Transm 114: 935-8, 2007
- 2007 **Pellicano C**, Benincasa D, Pisani V, Buttarelli FR, Giovannelli M & Pontieri FE. *Prodromal non-motor symptoms of Parkinson's disease*. Neuropsychiatr Dis Treatm 3: 145-51, 2007
- 2006 Buttarelli FR, Circella A, **Pellicano C**, Pontieri FE. *Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis*. EurJ Neurol, 13: 416-418, 2006.
- 2005 Pontieri FE, Ricci A, **Pellicano C**, Benincasa D & Buttarelli FR. *Minocycline in amyotrophic sclerosis: a pilot study*. Neurol Sci 26: 285-7, 2005

LANGUAGE ABILITIES

Italian	Native speaker
English	Highly proficient in spoken and written English
French	Good working knowledge in spoken and written French

I hereby authorize the processing of personal data in accordance with DL 196/03.

La sottoscritta dichiara di essere consapevole che il presente *curriculum vitae* sarà pubblicato sul sito istituzionale dell'Ateneo, nella Sezione "Amministrazione trasparente", nelle modalità e per la durata prevista dal d.lgs. n. 33/2013, art. 15.

Data 25 Jun 2021

f.to Dr Clelia Pellicano, MD, PhD